Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618718 | 0.89 | BRD4 (0.51) | BRD4MEN1KMT2ACNR2NPC1 | |
| SCHEMBL10147491 | 0.77 | BRD4 (0.53) | BRD4MEN1KMT2ACNR2NPC1 | |
| SCHEMBL10147510 | 0.77 | BRD4 (0.53) | BRD4MEN1KMT2ACNR2NPC1 | |
| SCHEMBL20291387 | 0.76 | BRD4 (0.46) | BRD4MEN1KMT2ACNR2NPC1 | |
| SCHEMBL23806102 | 0.76 | BRD4 (0.46) | BRD4MEN1KMT2ACNR2NPC1 | |
| SCHEMBL352100 | 0.76 | BRD4 (0.48) | BRD4MEN1KMT2ACNR2NPC1 | |
| SCHEMBL352017 | 0.76 | CNR2 (0.52) | BRD4MEN1KMT2ACNR2NPC1 | |
| SCHEMBL20291195 | 0.74 | BRD4 (0.50) | BRD4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20291057 | 0.74 | BRD4 (0.60) | BRD4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL20291059 | 0.71 | BRD4 (1.00) | BRD4MEN1KMT2ACNR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | BRD4 261/4885MEN1 4875/4885KMT2A 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.